Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

SNSS 7.46 -0.03 (-0.40%)
price chart
Wedbush Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Neutral
Wedbush downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Outperform to Neutral with a price target of $10 (unchanged).
Insider Selling: Eric Bjerkholt Sells 10000 Shares of Sunesis ...  Ticker Report
Hot Stocks Alert: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Keryx ...  Market News Call
Related articles »  
Sunesis Pharmaceuticals CFO Eric Bjerkholt Sells 10000 Shares (SNSS)
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings data on Tuesday, August 5th. The company reported ($0.20) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.17) by $0.03.
Insider Selling: Sunesis Pharmaceuticals major shareholder Sells 300700 ...  Watch List News (press release)
Related articles »  
Sunesis Pharmaceuticals Stock Rating Lowered by Wedbush (SNSS)
Sunesis Pharmaceuticals, Inc. logo Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by investment analysts at Wedbush from an �outperform� rating to a �neutral� rating in a note issued to investors on Friday, TheFlyOnTheWall.
Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short ...
Sunesis Pharmaceuticals is nearing a binary event with the top-line data readout of its Phase 3 Valor trial that is expected any day now.
Related articles »  
Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session, as the company saw its shares rise more than 9% on the day.
Related articles »  
Stocks to Keep Your Eyes On: Sunesis Pharmaceuticals, Inc. (SNSS), Aspen ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) plummeted 3.73 percent to $7.49 in the last trading session after Wedbush cut its ratings for the biopharmaceutical company from �Outperform� to �Neutral� in a research report sent to investors on August 29.
Massive Stock Sale at Sunesis Pharmaceuticals, Inc. (SNSS): 4 Insiders Unload ...
Yesterday, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) saw four of its insiders complete stock dispositions. The first three insiders to unload stock were James Barrett, Patrick Kerins, and Peter Barris, all of whom own over 10% of the company.
Insider Selling: Sunesis Pharmaceuticals Director Unloads 743700 Shares of ...  WKRB News
Sunesis Pharmaceuticals major shareholder Equity Opportunities Fu Growth ...  Watch List News (press release)
Related articles »  
Live News Buzz: IGI Laboratories, Inc.(NYSEMKT:IG), Sunesis Pharmaceuticals ...
Lakeway, NY - (MARKET NEWS CALL) - 8/29/2014�, an investment community with a special focus on updating investors with recent news on the U.S.
5 Stocks With High Institutional Ownership: Sunesis Pharmaceuticals, EXACT ...
Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.
Related articles »  
Sunesis Pharmaceuticals (SNSS) in Focus: Stock Rises 9.9%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session, as its shares rose almost 10% on the day.
Related articles »